Rocket Pharmaceuticals (RCKT) Long-Term Debt Issuances (2014 - 2016)

Rocket Pharmaceuticals has reported Long-Term Debt Issuances for 3 years, with the latest figure at -$52.0 million in Q4 2016.

• Quarterly Long-Term Debt Issuances fell 442.01% year-over-year to -$52.0 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$52.0 million (down 347.55% YoY) and the FY2016 annual result came in at $14000.0, down 99.93% from the prior year.
• Long-Term Debt Issuances fell to -$52.0 million in Q4 2016 per RCKT's latest filing, from $15.2 million in the prior quarter.
• Over five years, Long-Term Debt Issuances peaked at $21.0 million in Q1 2015 and troughed at -$52.0 million in Q4 2016.
• A 3-year average of -$6.1 million and a median of $715000.0 in 2014 frame the typical range for Long-Term Debt Issuances.
• The sharpest annual moves came in 2015 and 2016: Long-Term Debt Issuances soared 2025.87% in 2015, then tumbled 442.01% in 2016.
• Over 3 years, Long-Term Debt Issuances stood at $715000.0 in 2014, then jumped by 2025.87% to $15.2 million in 2015, then sank by 442.01% to -$52.0 million in 2016.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered -$52.0 million, $15.2 million, and -$15.2 million for Q4 2016, Q4 2015, and Q2 2015 respectively.